Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics.
A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockb
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh